



PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 3

Application Number 10/672,477

Filing Date September 26, 2003

First Named Inventor Rhonda A. Mills

Art Unit 1645

Examiner Name

Attorney Docket Number 121,013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>Dul</i>		ALBERIO, L., et al., "Rapid Determination of Anti-Heparin/Platelet Factor 4 Antibody Titers in the Diagnosis of Heparin-Induced Thrombocytopenia", Am J Med, 114:528-536 (2003)	
		AMIRAL, J., et al., "Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effectson platelet activation", Br J Haematol, 109:336-341 (2000)	
		BIRHIRAY, R.E., et al., Phenotypic transformation of CD52pos to CD52neg leukemic T cells as a mechanism for resistance to CAMPATH-1H", Leukemia, 16:861-864 (2002)	
		CHILVER-STAINER, L., et al., "Titre of anti-heparin/PF4-antibodies and extent of in vivo activation of the coagulation and fibrinolytic systems", Thromb Haemost, 91:276-282 (2004)	
		CHONG, B.H., et al., "Heparin-induced thrombocytopenia", J Thromb Haemost, 1:1471-1478 (2003)	
		CLARKE, L.E., "Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy", J Cutan Pathol, 30:459-462 (2003)	
		DAVIS, T.A., et al., "Therapy of B-Cell Lymphoma with Anti-CD20 Antibodies Can Result in the Loss of CD20 Antigen Expression", Clin Cancer Res, 5:611-615 (1999)	
		DEBOIS, W.J., et al., "Diagnosis and treatment of heparin-induced thrombocytopenia", Perfusion, 18:47-53 (2003)	
		DUMONT, F.J., "CAMPATH (alemtuzumab) for the treatment of chronic lymphocytic leukemia and beyond", Expert Rev Anticancer Ther, 2:23-35 (2002)	
<i>✓</i>		GILES, F.J., et al., "Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease", Br J Haematol, 123:850-857 (2003)	

Examiner Signature

David A. Saunders


Date Considered

10/10/06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/088 (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/672,477
Filing Date	September 26, 2003
First Named Inventor	Rhonda A. Mills
Art Unit	1645
Examiner Name	
Attorney Docket Number	121,013

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>DM</i>		GINALDI, L, et al., "Levels of Expression of CD52 in Normal and Leukemic B and T Cells: Correlation with In vivo Therapeutic Responses to Campath-1H", Leuk Res, 22:185-191 (1997)	
		GOBBI, G., et al., "New Laboratory Test in Flow Cytometry for the Combined Analysis of Serologic and Cellular Parameters in the Diagnosis of Heparin-Induced Thrombocytopenia", Cytometry, 58B:32-38 (2004)	
		KENNEDY, G.A., et al., "Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review", Br J Haematol, 119:412-416 (2002)	
		LINDHOFF-LAST, E., et al., "Determination of heparin-platelet factor 4-IgG antibodies improves diagnosis of heparin-induced thrombocytopenia", Br J Haematol, 113:886-890 (2001)	
		MASON, D.Y., et al., "Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen", Am J Pathol, 136:1215-1222 (1990)	
		REBELLO, P., et al., "Anti-globulin Responses to Rat and Humanized Campath-1 Monoclonal Antibody Used to Treat Transplant Rejection", Transplantation, 68:1417-1420 (1999)	
		REBELLO, P., et al., "Pharmacokinetics of CAMPATH-1H: assay development and validation", J Immunol Methods, 260:285-302 (2002)	
		REILLY, R.F., "The Pathophysiology of Immune-mediated Heparin-induced thrombocytopenia", Seminars in Dialysis, 16:54-60 (2003)	
		TAYLOR, V.C., et al., "Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism", Biochem J, 322(Pt 3):919-925 (1997)	
		TAZZARI, P.L., "Heparin-induced thrombocytopenia: detection of antiheparin/PF4 antibodies by means of heparin/PF4-coated beads and flow cytometry", Transfus Med, 12: 193-198 (2002)	

Examiner Signature	<i>Daina A. Saunders</i>	Date Considered	<i>10/10/06</i>
--------------------	--------------------------	-----------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete If Known	
		Application Number	10/672,477
		Filing Date	September 26, 2003
		First Named Inventor	Rhonda A. Mills
		Art Unit	1645
		Examiner Name	
Sheet 3 of 3	Attorney Docket Number	121,013	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DML ↓		UNTCH, B., et al., "Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia, The pathogenic role of IgG", Thromb Res, 105:117-123 (2002)	
		VITALE, M., et al., "Comparison Between Different Laboratory Tests for the Detection and Prevention of Heparin-Induced Thrombocytopenia", Cytometry, 46:290-295 (2001)	
		VUN, C.M., et al., "Anti-PF4-heparin immunoglobulin G is the major class of heparin-induced thrombocytopenia antibody: findings of an enzyme-linked immunofiltration assay using membrane-bound hPF4-heparin", Br J Haematol, 112:69-75 (2001)	
		International Council for Standardization in Haematology Expert Panel on Cytometry and Int'l. Soc. of Lab. Hematol. Task Force on Platelet Counting, "Platelet Counting by the RBC/Platelet Ratio Method, A Reference Method", Am J Clin Pathol, 115:460-464 (2001)	

Examiner Signature	David A. Saenclers	Date Considered	10/10/06
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Pocket No.: BECK1250	Application No.: 10/672,477
		Applicants: Mills et al.	Confirmation No.: 8232
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date: September 26, 2003	Group Art Unit: 4645 / 1644

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
<i>Dal</i>	AA	2003/0194818 A1	10/16/2003	Hechinger	436	513	09/13/2002

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
<i>Dal</i>	AB	1 387 171 A1	02/04/2004	EP	G01N	33/543	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

<i>Dal</i>	AC	Rodriguez-Caballero et al., "Flow Cytometric Analysis of Cytokine Responses in Stimulated Whole Blood: Simultaneous Quantitation of TNF- α -Secreting Cells and Soluble Cytokines", <i>Current Protocols in Cytometry</i> , 2003, 9.21.1-9.21.21

EXAMINER <i>David A. Saunders</i>	DATE CONSIDERED 10/11/06
--------------------------------------	-----------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: BECK1250	Application No.: 10/672,477
	Applicants: Mills et al.	Confirmation No.: 8232
INFORMATION DISCLOSURE STATEMENT		
BY APPLICANT	Filing Date: September 26, 2003	Group Art Unit: 1645

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA	2003/0194818 A1	10/16/2003	Hechinger	436	513	09/13/2002

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AB	1 387 171 A1	02/04/2004	EP	G01N	33/543	


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AC	Rodriguez-Caballero et al., "Flow Cytometric Analysis of Cytokine Responses in Stimulated Whole Blood: Simultaneous Quantitation of TNF-α-Secreting Cells and Soluble Cytokines", Current Protocols in Cytometry, 2003, 9.21.1-9.21.21

EXAMINER <i>David A. Saunders</i>	DATE CONSIDERED <i>10/11/06</i>
--------------------------------------	------------------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Form 1449

DUPLICATE
SUBMISSION



PTO/SF 08B

U.S. Department of Commerce
U.S. Patent and Trademark Office

Complete if Known

Application No.	10/672,477
Filing Date	September 26, 2003
First Named Inventor	Rhonda A. Mills
Art Unit	1645
Examiner Name	
Attorney Docket No.	121,013

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in capital letters), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>Jul</i>		LINDMO, T., et al., "Immunometric Assay by Flow Cytometry Using Mixtures of Two Particle Types of Different Affinity", <i>J. Immunol. Meth.</i> , 1990, 126:183-189
		SIIMAN, O., et al., "Preparation, Microscopy, and Flow Cytometry with Excitation into Surface Plasmon Resonance Bands of Gold or Silver Nanoparticles on Aminodextran-Coated Polystyrene Beads", <i>J. Phys. Chem.</i> , 2000, 104:9795-9810
		SIIMAN, O., et al., "Immunophenotyping Using Gold or Silver Nanoparticle-Polystyrene Bead Conjugates with Multiple Light Scatter", <i>Cytometry</i> , 2000, 41:298-307
		FRENGEN, J., et al., "A Sequential Binding Assay with a Working Range Extending Beyond Seven Orders of Magnitude", <i>J. Immunol. Meth.</i> , 1995, 178:11-140
		FRENGEN, J., et al., "Dual Analyte Assay Based on Particle Types of Different Size Measured by Flow Cytometry", <i>J. Immunol. Meth.</i> , 1995, 178:141-151
		CUSTER, M.C., et al., "A Biologic Assay for IL-4. Rapid Fluorescence Assay for IL-4 Detection in Supernatants and Serum", <i>J. Immunol. Meth.</i> , 1990, 128:109-117
		SIIMAN, O., et al., "Covalently Bound Antibody on Polystyrene Latex Beads: Formation, Stability, and Use in Analyses of White Blood Cell Populations", <i>J. Colloid Interface Sci.</i> , 2001, 234:44-58

Examiner

Signature

Darinda Saunders

Date Considered

10/11/06

*EXAMINER: Initial if citations considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional).



ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	Method for Simultaneous Evaluation of a Sample Containing Cellular Target and a Soluble Analyte						
<p>Application Number: 10/672477</p> <p>Confirmation Number: 8232</p> <p>First Named Applicant: Rhonda Mills</p> <p>Attorney Docket Number: 121013</p> <p>Art Unit: 1645</p> <p>Search string: (4376110 or 4528274 or 4886796 or 5006459 or 5162990 or 5168044 or 5171846 or 5240640 or 5248772 or 5426029 or 5459073 or 5466609 or 5525461 or 5527713 or 5552086 or 5567627 or 5639620 or 5658741 or 5707877 or 5756011 or 5776706 or 5811525 or 5935857 or 5945293 or 5981180 or 6074884 or 6268155 or 20020076833).pn.</p>							
<p>US Patent Documents</p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p>							
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
<input checked="" type="checkbox"/>	1	4376110	1983-03-08	David, et al.	B1		
<input checked="" type="checkbox"/>	2	4528274	1985-07-09	Carter, et al.	B1		
<input checked="" type="checkbox"/>	3	4886796	1989-12-12	Eichner, et al.	B1		
<input checked="" type="checkbox"/>	4	5006459	1991-04-09	Kung, et al.	B1		
<input checked="" type="checkbox"/>	5	5162990	1992-11-10	Odeyale, et al.	B1		
<input checked="" type="checkbox"/>	6	5168044	1992-12-01	Joyce, et al.	B1		
<input checked="" type="checkbox"/>	7	5171846	1992-12-15	Ravinder K. Gupta	B1		
<input checked="" type="checkbox"/>	8	5240640	1993-08-31	Siiman, et al.	B1		
<input checked="" type="checkbox"/>	9	5248772	1993-09-28	Siiman, et al.	B1		
<input checked="" type="checkbox"/>	10	5426029	1995-06-20	Rittershaus, et al.	B1		
<input checked="" type="checkbox"/>	11	5459073	1995-10-17	Wayne L. Ryan	B1		
<input checked="" type="checkbox"/>	12	5466609	1995-11-14	Siiman, et al.	B1		
<input checked="" type="checkbox"/>	13	5525461	1996-06-11	Charles W. Rittershaus	B1		

gal

<input type="checkbox"/>	14	5527713	1996-06-18	Bolton, et al.	B1
<input type="checkbox"/>	15	5552086	1996-09-03	Siiman, et al.	B1
<input type="checkbox"/>	16	5567627	1996-10-22	Brian C. Lehn	B1
<input type="checkbox"/>	17	5639620	1997-06-17	Siiman, et al.	B1
<input type="checkbox"/>	18	5658741	1997-08-19	Bolton, et al.	B1
<input type="checkbox"/>	19	5707877	1998-01-13	Siiman, et al.	B1
<input type="checkbox"/>	20	5756011	1998-05-26	Woodhead, et al.	B1
<input type="checkbox"/>	21	5776706	1998-07-07	Siiman, et al.	B1
<input type="checkbox"/>	22	5811525	1998-09-22	Charles W. Rittershaus	B1
<input type="checkbox"/>	23	5935857	1999-08-10	Riesgo, et al.	B1
<input type="checkbox"/>	24	5945293	1999-08-31	Siiman, et al.	B1
<input type="checkbox"/>	25	5981180	1999-11-09	Chandler, et al.	B1
<input type="checkbox"/>	26	6074884	2000-06-13	Siiman, et al.	B1
<input checked="" type="checkbox"/>	27	6268155	2001-07-31	Koo, et al.	B1

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
<i>JK</i>	1	20020076833	2002-06-20	Henry, et al.	A1		

Signature

Examiner Name	Date
<i>David A. Saunders</i>	<i>10/11/04</i>